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a b s t r a c t
Using a consensus epitope prediction approach, three rotavirus (RV) peptides that induce cytokine
secretion by CD4 T cells from healthy volunteers were identiﬁed. The peptides were shown to bind HLA-
DRB1n0101 and then used to generate MHC II tetramers. RV speciﬁc T cell lines speciﬁc for one of the
three peptides studied were restricted by MHC class II molecules and contained T cells that bound the
tetramer and secreted cytokines upon activation with the peptide. The majority of RV and Flu tetramerþ
CD4 T cells in healthy volunteers expressed markers of antigen experienced T cells, but only RV speciﬁc
CD4 T cells expressed intestinal homing receptors. CD4 T cells from children that received a RV vaccine,
but not placebo recipients, were stained with the RV-VP6 tetramer and also expressed intestinal homing
receptors. Circulating RV-speciﬁc CD4 T cells represent a unique subset that expresses intestinal homing
receptors.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Rotavirus (RV) is the leading worldwide cause of severe
gastroenteritis in children under the age of 5 years (Tate et al.,
2012). Two vaccines (Rotarix™ and Rotateq™) have been included
in national immunization programs in many countries (Glass et al.,
2012), but their efﬁcacy is relatively low in some African and Asian
countries, where they are most needed (Angel et al., 2012). Thus,
improvement of current vaccines or generation of new RV vaccines
is desirable; however, an important drawback to this end is the
lack of optimal immune correlates of protection after vaccination
(Angel et al., 2012).
The protective immune response to RV in humans and animals
is mediated by intestinal IgA (Blutt et al., 2012; Franco et al., 2006),
which is, at least partially, T cell dependent: on the one hand, in
the murine model the CD4 T cells are essential for the develop-
ment of RV-speciﬁc intestinal IgA (Franco and Greenberg, 1997).
On the other hand, children with T and/or B immunodeﬁciencies
get chronically infected with RV, suggesting that both arms of the
immune system are important in clearance of RV infection (Gilger
et al., 1992). Our group has observed that higher frequencies of RV-
speciﬁc CD8 and CD4 T cells secreting IFN-γ circulate in
symptomatically infected adults and RV-exposed laboratory work-
ers, compared with healthy volunteers. (Jaimes et al., 2002). In
contrast, children with RV diarrhea had low or below detection
levels of RV-speciﬁc CD8 and CD4 T cells secreting IFN-γ (Jaimes
et al., 2002; Mesa et al., 2010; Rojas et al., 2003). Consequently,
monitoring of RV-speciﬁc CD4 T cells responses after vaccination
may require a direct and highly sensitive assay.
The expression of tissue-homing receptors deﬁnes subsets of
memory T cells that preferentially home to the skin or gut (Butcher
and Picker, 1996; Sallusto and Lanzavecchia, 2009). These recep-
tors are imprinted by dendritic cells in developing T cells and
promote trafﬁcking properties based on the site-speciﬁc expres-
sion of their ligands (Sigmundsdottir and Butcher, 2008). Gastro-
intestinal associated lymphoid tissue dendritic cells metabolize
food-vitamin A into retinoic acid, which induces the T cells to
express high levels of the gut-homing receptors α4β7 and CCR9,
predisposing the migration of the recent activated T cells from the
blood to the effector sites in the gut mucosa (Mavigner et al.,
2012). The natural ligand of the α4β7 integrin is the mucosal
addressing cell adhesion molecule-1 (MAdCAM-1), which is
expressed by endothelial cells of the lamina propria along the
entire intestine. Whereas, CCL25, the ligand of CCR9, is only
expressed by small intestine endothelial and epithelial cells
(Mavigner et al., 2012). Thus, T cells that express both markers
are conditioned to home to the small intestine.
RV predominantly replicates in mature enterocytes of the small
intestine, but also has a systemic dissemination (Blutt et al., 2003)
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and, consequently, both intestinally and systemically primed T
cells are expected to be generated (Franco et al., 2006). Using
puriﬁed subsets of peripheral blood mononuclear cells (PBMC)
that express the intestinal homing receptor α4β7, we found that
RV-speciﬁc CD4 T cells secreting IFN-γ from adult volunteers
preferentially express this receptor (Rojas et al., 2003). With
similar studies other investigators have shown that in healthy
adults circulating CD4 T cells that proliferate in vitro in response to
RV also express α4β7 (Rott et al., 1997). All of these studies have
the drawback that subsets of T cells expressing the homing
receptor have to be puriﬁed before their identiﬁcation in the
functional studies, which may change their phenotype. Moreover,
no studies have assessed the expression of CCR9 on human RV-
speciﬁc T cells.
Recently, the use of MHC class II tetramers for characterization
of CD4 T cells populations (Vollers and Stern, 2008) has appeared
as a new important tool to characterize antigen-speciﬁc T cells
against different viruses (Nastke et al., 2012; Nepom, 2012). Also,
tetramers have been used to examine the CD4 T cells responses
after vaccination against inﬂuenza (Flu) (Danke and Kwok, 2003)
and anthrax (Laughlin et al., 2007). The tetramers permit the
ex vivo quantiﬁcation and phenotypic characterization of T cells
without T cell activation.
In the present study, we identiﬁed the ﬁrst HLA-DR1-restricted
human RV-speciﬁc CD4 T cell epitope, and used MHC class II
tetramers to characterize the phenotype of the T cells speciﬁc to this
epitope. T cells speciﬁc for the RV peptide tetramer, but not for a Flu
virus peptide-tetramer, expressed intestinal homing receptors. More-
over, antigen experienced CD4 T cells from children that received a
RV vaccine, but not from placebo recipients, were stained with the RV
tetramer and expressed intestinal homing receptors.
Results
Prediction of RV epitopes
We used a consensus approach that combined P9 binding and
SYFPEITHI presentation algorithms to predict HLA-DR1-restricted
T cell epitopes (Calvo-Calle et al., 2007) from the KU strain of RV
(Table S1). Thirty-nine 9-mer sequences with high scores were
selected: 11 were derived from non-structural proteins and the
remaining 28 were derived from structural proteins (Table S1).
Peptides were synthesized as 21-mers, containing the 9-mer
sequence of interest ﬂanked by six aa residues on each side.
Screening of peptide pools and identiﬁcation of individual peptides
recognized by CD4 T cells from healthy adults
The 39 peptides were organized in eight pools of ﬁve peptides
each (pool 8 only had four peptides) according to the algorithm
score; the ﬁve peptides with the lowest scores were arranged in
pool 1, and the four peptides with highest scores were joined in
the pool 8. We expected that HLA-DR1-peptides selected would be
recognized by CD4 T cells from individuals of other MHC haplo-
types, because of the broadly speciﬁc “promiscuous” peptide
binding motifs characteristic of most human MHC class II protein,
that give rise to the concept of “MHC class II supertypes”
(Greenbaum et al., 2011). For this reason, all 18 volunteers selected
for our screening experiments expressed MHC haplotypes belong-
ing to the DR-1 supertype (Table S2) (Greenbaum et al., 2011).
PBMC of 18 healthy volunteers were obtained and CD4 T cell
responses to pools of peptides were evaluated by ex-vivo intracel-
lular cytokine staining of IFN-γ and IL-2. CD4 T cells from four
volunteers (HA-02; HA-04; HA-05 and HA-06) responded against
the peptide pools: cells from volunteer HA-06 recognized pools
7 and 8 (Fig. 1A), cells from volunteer HA-05 recognized pool 5
(CD4 IL-2þ: 0,0232%), and cells from volunteers HA-02 (CD4 IL-
2þ: 0.0208%) and HA-04 (CD4 IL-2þ: 1.284%) recognized pool 7
(data not shown). Positive pools were deconvoluted to individual
peptides using the same assay. Fig. 1B shows the frequency of cells
from volunteer HA-06 producing IL-2 in response to peptides from
pools 7 and 8. Three peptides (VP6-7, NSP2-3, and VP3-4) were
found to induce IL-2 production by CD4 T cells from the HLA-DR1-
volunteers: VP6-7 induced IL-2 production in cells from volunteers
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Fig. 1. CD4 T cells from one healthy adult recognize peptide pools and individual
RV peptides. PBMC from HA-06 were stimulated with peptide pools (A),
or individual peptides (B), at a concentration of 1 mg/ml or with different doses
(C) during 10 h at 37 1C and for the last 5 h, 1 mg/ml of brefeldin A was added. The
frequencies of T cells producing IL-2 and IFN-γ were evaluated by intracellular
cytokine staining. SEB was used as a positive control. Responses were considered
positive if the number of IL-2 or IFN-γ-producing CD4 T cells was at least twice that
of the DMSO control and above 0.02% (dashed lines). In the experiments shown
T cells did not produce IFN-γ.
M. Parra et al. / Virology 452-453 (2014) 191–201192
HA-06 (Fig. 1B), HA-02, and HA-04; and also IFN-γ production in
cells from HA-06 (data not shown). In addition, VP3-4 induced IL-2
production in cells from volunteer HA-06 (Fig. 1B), and NSP2-3 in
cells from HA-04 (data not shown). No response was seen to
individual peptides of pool 5 from volunteer HA-05 (data not
shown).
The percentage of cells producing IL-2 in response to VP6-7
peptide used to stimulate PBMC from the volunteers HA-06
(Fig. 1C), HA-02, and HA-04 (data not shown) was dose dependent.
A similar result was obtained stimulating cells from volunteer
HA-06 with VP3-4 peptide (Fig. 1C), but no dose effect was
observed with cells from volunteer HA-04 stimulated with
NSP2-3 (data not shown).
RV peptides bind HLA-DR1 molecules
To evaluate if the initial 9-mer sequences deﬁned using pre-
diction algorithms bind to recombinant DR1 and DR4 MHC
molecules, the nine aa core of the peptides NSP2-3, VP3-4 and
VP6-7, with one aa addition at both ends, were synthetized and
tested for HLA-DR1 and HLA-DR4 binding in a competition binding
assay with a biotinylated high afﬁnity DR1- and DR4-binding
peptide from Flu haemagglutinin HA306–318 (Fig. 2). Compared to
HA peptide (IC50 96 nM), VP6-7 (IC50 2 nM) and NSP2-3 (IC50
15 nM) peptides bound to the HLA-DR1 molecules with relatively
higher afﬁnity and VP3-4 peptide bound with similar afﬁnity (IC50
73 nM). In contrast, all RV peptides show low afﬁnity binding to
the HLA-DR4 molecules (IC50 from 0.8 μM to 55 μM) (Fig. 2). Based
on these results, DR1 tetramers were synthetized with the RV
peptides NSP2-3, VP3-4, and VP6-7.
RV peptide VP6-7 is recognized by RRV speciﬁc T cell lines
To evaluate if the selected peptides were processed and
presented after viral infection, RRV-T cell lines were derived from
2 HLA-DR1 healthy volunteers (HA-02 and HA-41) and stained
with the three RV DR1-tetramers. RRV-T cell lines derived from
both volunteers only stained with VP6-7-tetramers (Fig. 3A and
data not shown). In addition, after restimulation of RRV-T cell lines
from volunteers HA-02 and HA-52 with RRV and VP6-7 peptide,
CD4 T cells producing TNF-α and/or IFN-γ were identiﬁed in both
cases (data not shown). Only one of these cell lines produced
cytokines after restimulation with NSP2-3 and neither of them
after restimulation with the VP3-4 peptide (data not shown).
RV peptides are presented to CD4 T cells in the context
of HLA-DR molecules
To determine if the three RV peptides were presented in the
context of HLA-DR molecules, peptide speciﬁc T cell lines from two
individuals (HA-02 [DRB1n01:01] and HA-06 [DRB1n01:02]) were
restimulated with the corresponding or control peptides in the
absence or presence of LB3.1 or SPV-L3 antibodies (directed
against HLA-DR or HLA-DQ molecules, respectively) and IFN-γ
production was evaluated by intracellular cytokine staining. The
frequency of CD4 T cells speciﬁc for VP6-7, NSP2-3 and VP3-4
producing IFN-γ decreased in the presence of LB3.1, but not in the
presence of SPV-L3 (Fig. 3B and data not shown): IFN-γ production
of VP3-4-T cell line from HA-02 volunteer was reduced approxi-
mately 55% in the presence of LB3.1 and only 6% in the presence of
SPV-L3 (Fig. 3B). From volunteer HA-06, only a VP6-7 speciﬁc T cell
line was obtained and the response of these cells was also
speciﬁcally inhibited by LB3.1 (data not shown). These results
provide additional evidence that RV peptides are presented in the
context of HLA-DR molecules, as indicated by tetramer staining.
VP6-7-MHC class II tetramers recognize functional peptide-speciﬁc
CD4 T cells in T cell lines
To provide additional evidence that VP6-7-tetramers recognize
functional VP6-7-speciﬁc CD4 T cells, T cell lines from two
volunteers (HA-02 and HA-19) were stained with tetramers (TRF
or VP6-7) and restimulated with VP6-7 peptide or DMSO (as
negative control), and the production of IFN-γ and TNF-α was
evaluated by intracellular cytokine staining. When the VP6-7-T cell
line from HA-02 was restimulated with VP6-7 peptide almost 70%
of the VP6-7-tetramer positive CD4 T cells produced cytokines
(TNF-α and/or IFN-γ), whereas in the control stimulated T cell line
only a low number (10%) of tetramer positive cells produced
cytokines (Fig. 3C). Similar results were obtained with a VP6-7-T
cell line derived from HA-19 volunteer (data not shown).
CD4 T cells from DR1 healthy adults proliferate and produce cytokines
after stimulation with RV peptides
Fresh PBMC from eight DRB1n0101 (HA-02, HA-15, HA-19,
HA-23, HA-29, HA-41, HA-51 and HA-52) and two DRB1n0102
healthy volunteers (HA-04 and HA-06) were stimulated with
the three RV peptides and evaluated 10 h later by intracellular
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Fig. 2. RV peptides bind HLA-DR1 but not HLA-DR4. Competition binding assays for RV (NSP2-3, VP3-4, and VP6-7) and Flu (HA306-318) peptides were performed. The
graphics show inhibition of binding of the biotinylated HA306-318 peptide to HLA-DR1 (A) and HLA-DR4 (B) by increasing amounts of RV and Flu peptides. Results were
analyzed using GraphPad Prism Software version 6.
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cytokine staining (IL-2, TNF-α and IFN-γ), and 5 days later for
proliferation using CFSE staining. Five DRB1n0101 (HA-15, HA-19,
HA-29, HA-51 and HA-52) and one DRB1n0102 (HA-04) healthy adults
had detectable levels of cytokine producing CD4 T cells (Table 1). CD4
T cells from HA-15 and HA-19 produced IL-2 after stimulation with
VP6-7. CD4 T cells from HA-51 and HA-52 produced TNF-α after
stimulation with VP6-7. Cells from HA-29 responded to VP3-4
stimulation producing TNF-α and cells from HA-04 responded to
VP3-4 producing TNF-α and to VP6-7 producing IFN-γ (Table 1). CD4 T
cells of HA-02 proliferated in response to the three RV peptides (NSP2-
3, VP3-4, and VP6-7), whereas CD4 T cells obtained from HA-19 and
HA-23 only proliferated to NSP2-3 stimulus. Thus, although approxi-
mately 60% of DR1 individuals have peptide-speciﬁc T cells detectable
by intracellular cytokine staining or proliferation, these responses do
not seem to occur simultaneously.
Antigen experienced CD4 T cells of healthy volunteers stained with
VP6-7-tetramer are enriched in the populations expressing the
intestinal homing receptors
Fresh PBMC from the same eight DRB1n0101 healthy donors
described above were stimulated with the three RV peptides in
order to generate speciﬁc T cell lines. Speciﬁc T cell lines for VP6-7
were obtained in all eight individuals and speciﬁc T cell lines for
NSP2-3 and VP3-4 each in four individuals (Table 2). T cell lines
from three volunteers (HA-02, HA-51 and HA-52) were expanded
with three peptides; T cell lines from two volunteers (HA-15 and
HA-19) were expanded with two peptides and T cell lines from
three volunteers only recognized VP6-7 (Table 2).
To compare the phenotype of RV- and Flu-speciﬁc T cells of the
volunteers in which T cell lines were expanded, PBMC were stained
with the TRF-, Flu-, and the corresponding RV-peptide tetramers
(Fig. 4A and B). The relative numbers of the CD4 T cells that stained
with the tetramers VP6-7 and Flu (medians of 27/6.0105 and
45/6.0105 CD4 T cells, respectively) were higher than those stained
with the TRF-tetramer (median of 9/6.0105 CD4 T cells) (Wilcoxon
test p¼0.011 and p¼0.003, respectively). Most of the CD4 T cells
stained with VP6-7- and Flu-tetramers (medians of 63.5% and 67.05%,
respectively) showed a phenotype of antigen experienced cells
(CD62LCD45RAþ / and CD62LþCD45RA) and no statistical differ-
ences were observed in the frequencies of these cells (Table 2, Fig. 4C).
Antigen experienced CD4 T cells stained with VP6-7-tetramer were
enriched in the populations expressing the intestinal homing recep-
tors: α4β7þCCR9þ and α4β7þCCR9 (Table 2, Fig. 4B and D). In con-
trast, antigen experienced CD4 T cells stained with Flu-tetramer were
enriched in the α4β7CCR9 population (Table 2, Fig. 4B and D).
RV-tetramerþ CD4 T cells in vaccinated children are enriched in the
populations expressing the intestinal homing receptors
To evaluate if RV vaccination induced the expansion of RV-CD4 T
cells of children, PBMC from three HLA-DR1-vaccinated and three
HLA-DR1-placebo recipient children, obtained 2 weeks after the
second dose of the RIX4414 human attenuated RV vaccine or placebo
(Rojas et al., 2007), were stained with the VP6-7- or control TRF-
tetramers, and the same panel of markers previously used in adults.
Because of the limited amount of sample available from vaccinated
children only direct PBMC staining and not T cell line experiments
were performed. The vaccinated, but not placebo recipient children,
had detectable plasma levels of RV-speciﬁc IgA after two doses of RV
vaccine (data not shown). In vaccinated children and placebo recipient
children from 40–71% and 0–8%, respectively, of VP6-7-tetramerþ
cells had the phenotype of antigen-experienced cells (data not shown).
In both groups of children, of the CD4 T cells stained with the TRF-
tetramer only 0–30% of cells had this phenotype (data not shown). In
vaccinated children, VP6-7 antigen experienced CD4 T cells were
detected at low frequencies (0.001–0.1%). In all 3 cases, most of the
antigen experienced CD4 tetramerþ T cells expressed α4β7, and in
two children (Fig. 5A, two top panels), most cells expressed both, α4β7
and CCR9, homing receptors. In vaccinated children the TRF-tetramer
Table 1
Cytokine production and proliferation of CD4 T cells after stimulation with RV
peptides.
Healthy
adult
Peptide
stimulus
CD4 T cytokine
production
CD4 T
proliferation
HA-02 NSP2-3  þ
VP3-4  þ
VP6-7  þ
HA-15 NSP2-3  
VP3-4  
VP6-7 IL-2(þ) 
HA-19 NSP2-3  þ
VP3-4  
VP6-7 IL-2(þ) 
HA-23 NSP2-3  þ
VP3-4  
VP6-7  
HA-29 NSP2-3  
VP3-4 TNF-α(þ) 
VP6-7  
HA-41 NSP2-3  
VP3-4  
VP6-7  
HA-51 NSP2-3  N.D.
VP3-4  N.D.
VP6-7 TNF-α(þ) N.D.
HA-52 NSP2-3  N.D.
VP3-4  N.D.
VP6-7 TNF-α(þ) N.D.
HA-04a NSP2-3  N.D.
VP3-4 TNF-α(þ) N.D.
VP6-7 IFN-γ(þ) N.D.
HA-06a NSP2-3  
VP3-4  
VP6-7  
þ , at least two-times background values.
N.D.: not done.
a HLA DRB1 0102 Healthy volunteer.
Fig. 3. Response of RRV and peptide speciﬁc T cell lines. (A) A RRV-T cell line was obtained from a healthy adult (HA-02), then restimulated with RRV, NSP2-3, VP3-4 or
VP6-7, and ﬁnally stained with the TFR-tetramer or the corresponding RV-tetramers. Left panel: RRV-T cell line restimulated with RRV and stained with the TRF-tetramer.
Middle panel: RRV-T cell line restimulated with NSP2-3 peptide and stained with the NSP2-3-tetramer. Right panel: RRV-T cell line restimulated with VP6-7 peptide and
stained with the VP6-7-tetramer. This T cell line only recognizes the VP6-7 tetramer. (B). A VP3-4 speciﬁc T cell line from HA-02 was restimulated with DMSO (upper left
panel), VP1-4 as a control peptide (upper right panel), or VP3-4 in the absence (upper center panel) or in the presence of an isotype control antibody (lower left panel), LB3.1
(lower center panel), or SPV-L3 (lower right panel) antibodies, which are directed against HLA-DR or HLA-DQ molecules, respectively, and the frequencies of cells producing
IFN-γwere evaluated by intracellular cytokine staining. (C) A VP6-7 speciﬁc T cell line from HA-02 was stimulated with DMSO (left panels) or VP6-7 (middle and right panels)
for 6 h at 37 1C and stained with the VP6-7-tetramer (upper right and left panels) or TRF-tetramer (upper center panels). Tetramerþ cells were evaluated by intracellular
cytokine staining for TNF-α and IFN-γ production (lower panels). Numbers inside all graphics represent percentages of populations. Responses were considered positive if the
frequency of TNF-α and/or IFN-γ-producing CD4 T cells was at least twice that of the DMSO control stimulated cells.
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(Fig. 5A, left panels) stained from 4 to 10 times less antigen
experienced cells than the VP6-7-tetramer (from o0.0001% to
0.01%). In placebo recipients (Fig. 5B), VP6-7- and TRF-tetramers
detected antigen experienced CD4 T cells at similar low levels
(o0.0001–0.003%).
Discussion
We have identiﬁed a RV CD4 T cell epitope (VP6-7) and shown that
cells stained with HLA-DR1 tetramers loaded with a peptide corre-
sponding to this epitope, but not a Flu peptide, expressed intestinal
homing receptors (Fig. 4). Moreover, studies with a low number of
vaccinated children showed that this type of reagent might be useful
to monitor the RV CD4 T cell response in vaccine trials (Fig. 5).
Of 39 predicted epitopes, three peptides were identiﬁed by
screening of PBMC from healthy adults by intracellular cytokine
staining; all of them also bound to HLA-DRB1n0101 molecules
(Figs. 1 and 2). The VP6-7 peptide is probably processed and
presented after RV infection, since it was recognized by a
rotavirus-T cell line (Fig. 3A). Moreover, peptide speciﬁc T cell
lines were DR-MHC restricted (Fig. 3B) and VP6-7-tetramers were
recognized by cells of vaccinated but not placebo recipient
children (Fig. 5), characterizing this peptide as a RV epitope. This
epitope overlaps totally with one previously found in mice (Baños
et al., 1997) and partially with a VP6 epitope found in Rhesus
macaques (Zhao et al., 2008), which suggests that this region is
particularly prone to be recognized by CD4 T cells. Although a RV
speciﬁc class II restricted human T cell epitope had been previously
described (Honeyman et al., 2010), our studies are the ﬁrst to
characterize epitope speciﬁc CD4 T cells with tetramers.
HLA supertypes are deﬁned as a set of HLA (class I or II)
associated with largely overlapping peptide/binding repertoires.
Recently, three different class II DR supertypes were classiﬁed
(main DR, DR4 and DRB3) (Greenbaum et al., 2011), and all of the
healthy adults volunteers for our screening experiments were
selected for having the main DR supertype, which includes HLA-
DR1 and many other class II molecules. Contrary to our expecta-
tions, only HLA-DR1 healthy adults recognized three peptides.
However, in one DRB1n0102 individual VP6-7 T cell line were
generated and their stimulation was inhibited by an anti-DR
monoclonal antibody, suggesting that at this level promiscuity
for HLA binding exists. The levels of promiscuity of viral epitopes
varies between studies from low (Kwok et al., 2008; Nepom, 2012)
to moderate (Roti et al., 2008). Further studies are necessary to
clarify the reasons for these differences.
Ex vivo tetramer staining of PBMC from healthy adults showed that
CD4 T cells speciﬁc for the VP6-7 peptide expressed intestinal homing
receptors. This result is in agreement with our previous report, in
which we observed that RV-speciﬁc IFN-γ secreting CD4 T cells from
adult volunteers preferentially express the intestinal homing receptor
α4β7 (Rojas et al., 2003). The present ﬁndings extend these results by
Table 2
Ex vivo phenotyping of Tetramerþ CD4 T cells of DRB1n0101 healthy adults with RV peptide speciﬁc T cell lines.
Healthy adult Peptide
tetraer
No. of Tetþ /6.0105
CD4þ T cells
% Antigen
experienced T cellsa
% α4β7(þ)
CCR9() b
% α4β7(þ)
CCR9(þ)b
% α4β7()
CCR9()b
% α4β7()
CCR9(þ)b
HA-02 TRF 8 54.5 33.3 33.3 33.3 0
FLU 36 68.4 42.3 7.69 50 0
NSP2-3 10 53.8 85.7 14.3 0 0
VP3-4 16 61.1 54.5 9.09 27.3 9.09
VP6-7 28 85.7 63.3 26.7 3.33 6.67
HA-15 TRF 4 0 c c c c
FLU 30 83.3 25 12.5 62.5 0
VP3-4 16 23.1 50 0 50 0
VP6-7 22 63.2 63.6 27.3 9.09 0
HA-19 TRF 10 85.7 8.33 33.3 33.3 25
FLU 24 65.7 21.7 0 78.3 0
NSP2-3 18 48.1 30.8 7.69 61.5 0
VP6-7 26 64.1 28 4 64 4
HA-23 TRF 8 57.1 25 25 50 0
FLU 60 91.2 32.7 3.85 61.5 1.92
VP6-7 24 87 75 15 10 0
HA-29 TRF 14 50 0 50 50 0
FLU 48 59.3 6.25 12.5 81.2 0
VP6-7 32 38.9 57.1 14.3 28.6 0
HA-41 TRF 3 100 33.3 0 66.7 0
FLU 42 97.1 3.03 0 90.9 6.06
VP6-7 25 67.3 50 0 50 0
HA-51 TRF 98 36.7 44.8 20.7 27.6 6.9
FLU 155 40.6 50.7 15.5 31 2.82
NSP2-3 63 31.7 34.6 30.8 26.9 7.69
VP3-4 54 37.5 45.8 12.5 29.2 8.33
VP6-7 50 41.5 58.8 23.5 5.88 11.8
HA-52 TRF 72 27.3 66.7 0 33.3 0
FLU 284 25.4 40.3 8.06 50 1.61
NSP2-3 140 17 55.6 11.1 27.8 5.56
VP3-4 149 22.6 35.7 0 57.1 7.14
VP6-7 134 16.5 31.2 25 43.7 0
a Antigen experienced cells are CD62L , CD45RAþ / and CD62Lþ CD45RA (Fig. 4B).
b Percentages correspond to antigen experienced cells.
c No antigen experienced cells were identiﬁed.
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showing that RV-tetramerþ antigen experienced (CD62LCD45
RAþ / and CD62LþCD45RA) CD4 T cells express both α4β7 and
CCR9 and, thus, are prone to home to the small intestine. Compared to
total non-antigen speciﬁc T cells, VP6-7 speciﬁc T cells are enriched
approximately 10 times in CCR9 expressing cells (Fig. 4A and B),
indicating that this is indeed a unique subset. Further studies are
necessary to determine if these circulating dual α4β7 and CCR9
expressing RV-speciﬁc T cells have a unique TCR repertoire.
The generation of RRV- or RV peptide-speciﬁc T cell lines
support the results obtained with ex vivo tetramer staining.
Characterization of T cell lines expanded with RRV showed that
VP6-7 and NSP2-3 are processed and presented by infected cells
(Fig. 3A and data not shown). However, peptide-speciﬁc T cell lines
were obtained after stimulation of PBMC with all three peptides
(Table 1). Moreover, responses of T cell lines speciﬁc for the three
peptides generated from PBMC obtained from an HLA-DRB1n0101
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Fig. 4. Phenotype and expression of homing receptors of CD4 tetramerþ T cells of healthy adults. Fresh PBMC were obtained from HLA-DRB1n0101 healthy adults and stained
with the Flu-tetramer (left panels), the TRF-tetramer (center panels) or the VP6-7-tetramer (right panels) and antibodies against differentiation markers and intestinal homing
receptors. After gating on live CD3 T cells, total (A) or tetramerþ (B) CD4 T cells (top panels) were analyzed to identify antigen experienced T cells CD62LCD45RAþ / and
CD62LþCD45RA (middle panels). The expression of α4β7 and CCR9 intestinal homing receptors was evaluated in antigen experienced cells (lower panels). Numbers in
parenthesis in the lower row dot plots indicate number of events. Results from the eight volunteers for antigen experienced T cells VP6-7-tetramerþ and Flu-tetramerþ cells
(C) and the expression of intestinal homing receptors (D) are summarized. Statistically signiﬁcant differences determined with Wilcoxon tests are shown.
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healthy adult were signiﬁcantly blocked with an antibody against
DR and poorly against an antibody to DQ molecules (Fig. 3B and
data not shown), suggesting that the VP6-7 epitope and the two
candidate RV-epitopes (NSP2-3 and VP3-4) were presented in the
context of HLA-DR molecules. T cell lines expanded with virus
lysate preparations might select clonotypes associated with immu-
nodominant peptides over low frequency and/or slowly growing
clonotypes (Nastke et al., 2012). Thus, in some of the experiments
with the RRV-T cell lines the responses to the NSP2-3 and VP3-4
candidate epitopes might have been masked.
The simultaneous staining of the majority of cytokine secreting
cells from a VP6-7 T cell line with the VP6-7 tetramer (Fig. 3C)
supports the speciﬁcity of the tetramer staining. Moreover, they
show that most cells stained with the tetramer are functional.
A correlation between cells staining with the tetramer and those
producing cytokines ex vivo is difﬁcult to establish, because of the
low or inexistent level of cytokine secreting cells speciﬁc for the
RV peptides (Table 1). However, the capacity of the tetramers to
identify speciﬁc T cells ex vivo seems more sensitive than the
intracellular cytokine staining and proliferation assays (Table 1)
and, thus, more suited to vaccine studies in children. Nonetheless,
it is possible that some of the cells stained with the tetramer
might be secreting cytokines not evaluated.
Staining of cells from vaccinated and placebo recipient children
with the VP6-7 tetramer showed that VP6-7-speciﬁc CD4 T cells
could be expanded after RV vaccination. Although the numbers of
cells observed in the vaccinated children were low (Fig. 5A), they
were all, as expected, α4β7 and in two cases they also expressed
CCR9. The cells used in the present study had been frozen over
seven years (Rojas et al., 2007), and it is expected that studies with
fresh cells may permit to obtain more cells to study and increase in
the sensitivity of the assay. Further studies are necessary to
conﬁrm that CD4 T cells from HLA-DR1 vaccinated children
recognize the RV epitope we have identiﬁed.
In conclusion, we have shown that CD4 T cells speciﬁc for a RV
epitope express intestinal homing receptors, which supports the
hypothesis that cells primed in peripheral compartments may
constitute a separate lineage (Sallusto and Lanzavecchia, 2009).
We also describe MHC tetramers that could be used to analyze RV-
speciﬁc CD4 T cell responses in vaccine studies. Similar studies in
the context of other MHC haplotypes are needed to expand the
number of tetramers available to monitor the CD4 T cell response to
RV vaccines and, hopefully, develop better correlates of protection.
Methods
Epitope prediction and peptides synthesis
To predict HLA-DR1 (DRB1n0101) binding epitopes, we used the
sequences of the RV strain KU G1P[8] form the NCBI genome
databases (BAA84966, BAA84967, Q82050.1, BAA84969, BAA84970,
AAK15270.1, BAA84962, BAA84963, BAA84964, P13842, BAA84965,
and BAA03847). Each potential 9-mer binding frame was evaluated
using two independent prediction algorithms: P9 (Calvo-Calle et al.,
2007; Hammer et al., 1994; Nastke et al., 2012; Sturniolo et al., 1999)
and SYFPEITHI (Schuler et al., 2007), as previously described (Calvo-
Calle et al., 2007; Nastke et al., 2012). Potential epitopes were selected
using cutoff scores of Z1.5 for P9 and Z29 for SYFPEITHI. Overall,
1440 possible 9-mer minimal epitopes were evaluated and 39
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Fig. 5. Expression of homing receptors on antigen experienced (CD62LCD45RAþ / and CD62LþCD45RA) CD4 T cells from RV vaccinated and placebo recipient children.
Frozen PBMC from HLA-DRB1n0101 RV vaccinated (A) or placebo recipient children (B) were stained as in Fig. 4 with the TRF-tetramer (left panels) and VP6-7-tetramer (right
panels). Dot plots show the expression of α4β7 and CCR9 intestinal homing receptors of CD4-tetramerþ antigen experienced cells from individual children. Numbers in
parenthesis in the dot plots indicate number of events.
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potential epitopes, scoring highly for both algorithms, were selected
(Supplementary Table 1), extended by six residues on each side,
and synthesized (Sigma-Aldrich PEPscreens) with an acetylated
N-terminal and amidated C-terminal.
Subjects
After written informed consent was signed, blood samples
were obtained from 52 healthy volunteers, 23–52 years old that,
as expected, had serum antibodies against RV. Frozen PBMC from
35 RV IgA seropositive vaccinated children and 24 RV seronegative
placebo recipient children (samples from a previous study (Rojas
et al., 2007)), in whom the informed consent authorized further
studies, were also assessed. This was a double-blind randomized
controlled study, in which children received two doses of either
placebo (n¼160) or 106.7 focus-forming units of the attenuated
RIX4414 human RV vaccine (precursor of the Rotarix™ vaccine,
n¼159). The ﬁrst and second doses were administered at 2 and
4 months of age, respectively, and children were bled 14–16 days
after each dose. Studies were approved by the Ethics Committee of
the San Ignacio Hospital and Pontiﬁcia Universidad Javeriana.
Human haplotype determination
DNA was obtained from blood samples using Illustra blood
genomicPrep Mini Spin Kit (G/E healthcare, UK Buckinghamshire),
according to manufacturer's instructions. The HLA class II haplo-
type was determined using All set Gold-SSP HLA DRDQ low
resolution Kit (Invitrogen Corporation, Wisconsin USA), PCR-
based protocols, according to manufacturer's instructions. All
samples identiﬁed as a DRB1n01 in low resolution were analyzed
for high-resolution using the All set Gold-SSP HLA DRB1n01 high-
resolution Kit (Invitrogen Corporation, Wisconsin USA), according
to manufacturer’s instructions. (Supplementary Table 2).
Antigen stimulation of PBMC and intracellular cytokine staining
PBMC were puriﬁed from heparinized whole-blood samples by
Ficoll-Hypaque gradients (Lympho Separation Medium, MP Bio-
medicals). The cells were washed twice with RPMI containing
20 mM HEPES, 100 U of penicillin/ml, and 100 mg of streptomycin/
ml plus 10% fetal bovine serum (FBS) (all from GIBCO, Carlsbad, CA,
USA) (complete medium) and re-suspended in 1 ml of AIM-Vs
medium (life technologies, Carlsbad, CA, USA). PBMC (1106 cells
in a ﬁnal volume of 1 ml) were stimulated with the supernatant of
MA104 cells infected with RRV (Rhesus RV, MOI:7), the super-
natant of mock-infected MA104 cells (negative control), the super-
antigen staphylococcal enterotoxin B (SEB; Sigma, St Louis, Mo,
USA), peptides pools (5 peptides per pool at 1 mg/ml each) or
individual peptides at different concentrations. Anti-CD28 (0.5 mg/
ml) and anti-CD49d (0.5 mg/ml) (both from BD Biosciences, San
Jose, CA) monoclonal antibodies were added to each sample as co-
stimulators (Waldrop et al., 1997, 1998). Antigen stimulation was
done in 15 ml polystyrene tubes (Becton Dickinson Falcon Lab-
ware, Franklin Lakes, N.J., USA) incubated with a 51 slant for 10 h at
37 1C with 5% CO2. The last 5 h of the incubation included brefeldin
A (10 mg/ml; Sigma) to block the secretion of cytokines. At the end
of the incubation, the cells were washed once with PBS–0.5%
bovine serum albumin (Merck, Darmstadt, Germany) 0.02%
sodium azide (Mallinckrodt Chemicals, Paris, Ky.) (Staining Buffer).
Then, a 2 mM ﬁnal concentration of EDTA (GIBCO, N.Y. USA) in PBS
was added for 10 min to detach plastic-adherent cells, and the
samples were washed once more with Staining Buffer. PBMC were
stained with Aqua viability reagent (Invitrogen Molecular Probes,
Eugene, OR) in PBS for 10 min at room temperature (RT), and the
cells were stained with monoclonal antibodies (Mabs) against
CD14-V500 and CD19-V500, as a dump channel, CD3-paciﬁc blue,
CD4-PerCP-Cy5.5, and CD8-APC-H7 for 20 min at RT (all from BD
Biosciences, San Jose, CA). After two wash steps with Staining
Buffer, cells were treated with Citoﬁx/Citoperm solution (BD
Biosciences, San Jose, CA) for 30 min at 4 1C and washed twice
with 1 ml of Perm/Wash solution (BD Bioscience, San Jose, CA).
Then, Mabs against IL-2-FITC, IFN-γ-PE-Cy7 and TNF-α-APC (all
from BD Biosciences) were added and incubated for 20 min at RT.
Production of IL-2 and IFN-γ by RV stimulated T cells was observed
in our previous work; TNF-α secretion was also evaluated to make
a more comprehensive analysis of multifunctional T cells
(Gattinoni et al., 2011). Finally, the cells were washed twice with
Perm/Wash, resuspended in 250 ml of Perm/Wash, acquired in a
FACSAria ﬂow cytometer (BD Biosciences, San Jose, CA) and
analyzed with FlowJo software v.9.3.2.
Peptide binding assays
Peptide binding to DR1 and DR4 was analyzed using an ELISA-
based competition assay, as previously described (Parra-López
et al., 2006). Puriﬁed HLA-DR1 or DR4 molecules (0.05 mM) were
diluted with freshly prepared binding buffer (100 mM citrate/
phosphate buffer [pH 5.4], 0.15 mM NaCl, 4 mM EDTA, 4% NP-40,
4 mM PMSF, and 40 mg/ml for each of the following protease
inhibitors: soybean trypsin inhibitor, antipain, leupeptin and
chymostatin) containing 0.025 mM biotin-labeled hemagglutinin
HA306–318, a well described binding peptide from Flu hemaggluti-
nin (PKYVKQNTLKLAT) (Roche and Cresswell, 1990), and various
concentrations of unlabeled competitor peptide (HA306-318, NSP2-3
(SGNVIDFNLLDQRIIWQNWYA), VP3-4 (YNALIYYRYNYAFDLKR-
WIYL) and VP6-7 (DTIRLLFQLMRPPNMTPAVNA)) in a total volume
of 120 ml. Peptides were diluted from stock solutions in binding
buffer. After 48 h of incubation at RT, 100 ml were transferred to
96-well ELISA microtiter plates (Immuno Modules MaxiSorp,
Nunc, Denmark), which had been previously coated overnight
with a 10 mg/ml anti-HLA-DR Mab LB3.1, washed, and subse-
quently blocked with PBS containing 3% bovine serum albumin.
After 2 h of incubation at RT, plates were washed with PBS, 0.05%
Tween-20 and incubated for 1 h with phosphatase-labeled strep-
tavidin (KPL, Maryland, USA). Captured biotin-labeled peptide/DR
complexes were revealed with 4-nitrophenylphosphate substrate
(KPL, Maryland, USA). For determining peptide binding to HLA-DR
molecules a Ultramark ELISA plate reader (Bio-Rad, CA, USA) with
a 405 nm ﬁlter was used. Results at each concentration are
expressed normalized with respect to the maximum observed
binding, and used to calculate IC50 values.
Carboxyﬂuorescein succinimidyl ester (CFSE) proliferation assay
Proliferation of cells was evaluated by CFSE staining as reported
by Quah (Quah and Parish, 2010; Quah et al., 2007), with some
modiﬁcations. Brieﬂy, 410106 fresh PBMC were resuspended
in 1 ml of PBS 1X, placed in a 15 ml conical tube, and stained with
CFDA-SE (CellTrace™ CFSE Cell Proliferation Kit). The cells were
incubated 5 min at RT, protected from light, and then washed
three times with 10 ml of PBS 1X-FBS 5% at RT. Finally, the cells
were diluted in 1 ml of RPMI supplemented with 10% ABþ human
serum (Multicell, human serum AB, Wisent INC, Canada). After
CFSE staining, PBMC were stimulated with SEB and three RV
peptides (NSP2-3, VP3-4, and VP6-7) for 5 days at 37 1C with 5%
CO2. Then, cells were harvested, washed twice with PBS 1X, and
stained with Violet viability reagent (Invitrogen Molecular Probes,
Eugene, OR) in PBS for 10 min; Mabs against CD3-PE, CD4-PerCP-
Cy5.5 and CD8-APC-H7 were added and incubated for 30 min at
RT. Finally, the cells were resuspended in 250 ml of PBS, acquired in
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a FACSAria ﬂow cytometer (BD Biosciences, San Jose, CA) and
analyzed with FlowJo software v.9.3.2.
T cell lines
T cell lines were generated from PBMC. 12106 PBMC per
well were incubated in 24-well plates in 1 ml of RPMI 1640
supplemented with ABþ human serum 10% (Multicell), 100 U/ml
penicillin, 100 μg/ml streptomycin, 1 mM sodium pyruvate, 2 mM
L-glutamine, and 1 mM nonessential amino acids. Antigen-speciﬁc
populations were expanded by culture in the presence of NSP2-3,
VP3-4 or VP6-7 peptides (10 mg/ml) or RRV infected MA104 cell
lysate (MOI:7). After 48 h of incubation at 37 1C with 5% CO2, fresh
T cell medium supplemented with 100 U/ml IL-2r (Proleukin;
Chiron Corporation, Emeryville, CA) was added. This last step
was repeated every 2 days until the culture completed 12 days.
Then, autologous non-irradiated PBMC (ratio 2:1), pulsed with or
without peptide (10 mg/ml) for 1 h, were used as source of antigen-
presenting cells to stimulate the T cell lines. Finally, T cell lines
were evaluated by ICS, as described above. In some cases, the cells
were stained as described below with the class II tetramer.
Class II tetramer staining of PBMC from adults and children
Biotinylated HLA-DR1-peptide complexes were prepared
using proteins produced in insect cells, as previously described
(Cameron et al., 2002). Class II tetramers with different peptides
(HA306-318, a transferrin [TRF] control peptide [RVEYHFLSPYVSR-
KESP (Chicz et al., 1992)], NSP2-3, VP3-4 or VP6-7) were prepared
with streptavidin-PE (Invitrogen, MD, USA) from a stock solution
at a ﬁnal concentration of 1 mg diluted in 50 ml of PBS 1X. Fresh
PBMC obtained from 8 DR1 healthy adults were washed twice in
PBS 1X and distributed in 5 ml polystyrene tubes (5106 cells/
50 ml per tube). Frozen PBMC of three vaccinated or three placebo
recipient HLA-DR1 children were thawed at 37 1C and washed
twice with a 5 ml Benzonases (Novagen, San Diego, CA) solution
pre-heated at 37 1C. Then, the cells were distributed in 5 ml
polystyrene tubes. Fifty ml of Dasatinibs (Bristol-Myers Squibb
Company Princeton, NJ 08543 USA) solution (100 mM) was added
to each tube and incubated for 30 min at 37 1C (Lissina et al.,
2009). Later, 10 ml of ABþ human serum was mixed with the cells
just before tetramer solution (1 mg) was added and incubated for
120 min at RT. Unlabeled mouse anti-CCR9 Mab was added and
incubated for 20 min at RT, then the cells were washed once
with PBS 1X, followed by addition of goat anti-mouse antibodies
(AF-488 or Paciﬁc Blue [Invitrogen Corporation, Wisconsin USA])
and incubated for 20 min at RT. The cells were washed once with
PBS 1X, then Aqua reagent was added and incubated for 10 min at
RT; subsequently, Mabs against CD14-V500 and CD19-V500, as a
dump channel, CD3 (Paciﬁc Blue or AF-700), CD4-PerCP-Cy5.5,
CD8-APC-H7, CD45RA (FITC or PE-Cy7), CD62L-V450 or CCR7-PE-
Cy7, and α4β7-APC (ACT-1) were added and incubated for 20 min
at RT. Cells were washed and resuspended in 400 ml of PBS-BSA-
sodium azide, acquired in a FACSAria ﬂow cytometer (BD Bios-
ciences, San Jose, CA) and analyzed with FlowJo software v.9.3.2.
ELISA for RV-speciﬁc IgA in plasma
For detection of RV-speciﬁc IgA, 96-well vinyl microtiter plates
were coated with 70 ml of a 1:10 dilution (in PBS, pH 7.4) of super-
natant from RF (bovine RV) virus-infected MA104 cells or the super-
natant of mock-infected MA104 cells (negative control) and incubated
overnight at 4 1C. The wells were then blocked with 150 ml of 5%
nonfat powdered milk plus 0.1% Tween-20 in PBS (5% BLOTTO) and
the plates were incubated at 37 1C for 1 h. Then, the BLOTTO was
discarded, and 70 ml of serial plasma dilutions in 2.5% BLOTTO were
deposited in each well. After 2 h of incubation at 37 1C, the plates were
washed three times with PBS-Tween-20, and 70 ml of biotin-labeled
goat anti-human IgA (Kirkegaard & Perry Laboratories, Gaithersburg,
Md.) diluted (1:1000) in 2.5% BLOTTO was added to the plates. The
plates were then incubated for 1 h at 37 1C. After three washes with
PBS-Tween-20, 70 ml of streptavidin-peroxidase (Kirkegaard & Perry
Laboratories, Gaithersburg, Md.) diluted (1:1000) in 2.5% BLOTTO was
added, and the plates were incubated for 1 h at 37 1C. After three
washes with PBS-Tween-20, the plates were developed using 70 ml of
tetramethyl benzidine substrate (TMB; Sigma, St. Louis, MO). The
reaction was stopped by the addition of 17.5 ml of sulfuric acid (2 M).
Absorbance was read at 450 nm wavelength on an ELISA plate reader
(Multiskan EK, Thermolab Systems). Samples were considered positive
if optical density (OD) in the well was 40.1 OD units and were two
times higher than the OD of the negative control (Rojas et al., 2007).
Statistical analyses
Analysis was performed with GraphPad Prism version 6.
Differences between groups were evaluated with the nonpara-
metric Wilcoxon test.
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